Bruker Corporation BRKR
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +21.14%
- 1 year
- +56.79%
- Open
- 59.47
- Prev close
- 62.00
- Mkt cap
- 8.70B
- Vol
- 1.92M
- Avg vol
- 2.30M
- EPS
- -0.70
- P/E
- 0.00
- Div yield
- 0.32%
More statistics
- Low
- 56.00
- High
- 60.17
- Forward P/E
- 23.75
- Beta
- 1.22
- Short ratio
- 5.27
- Inst. own
- 95.54%
- Dividend
- 0.20
- Ex-div date
- Sep 20, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 58.96
- 200-d avg
- 50.18
- 1y target
- 63.83
News
1 week ago benzinga.com
SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today
SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
1 week ago businesswire.com
Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2026 financial results before market opening on Wednesday, November…
2 weeks ago gurufocus.com
Is Bruker Corp (BRKR) a Bargain After 3.1% Drop? GF Value Says Undervalued
On October 16, 2026, Bruker Corp (BRKR) shares fell 3.1% to $54.80, reflecting a challenging price performance context with a 52-week range of $32.37 to $66.98.
2 weeks ago benzinga.com
This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded CTNM, CC, ACI, BRKR and SAFE; targets fell for CTNM, CC and ACI, while BRKR received a new $60 target.
-
2 weeks ago benzinga.com
JP Morgan Downgrades Bruker to Neutral, Announces $60 Price Target
JP Morgan analyst Casey Woodring downgrades Bruker (NASDAQ:BRKR) from Overweight to Neutral and announces $60 price target.
-
2 weeks ago benzinga.com
TD Cowen Maintains Hold on Bruker, Raises Price Target to $62
TD Cowen analyst Kyle Boucher maintains Bruker (NASDAQ:BRKR) with a Hold and raises the price target from $60 to $62.
3 weeks ago zacks.com
Bruker Gains 66.3% in a Year: What's Driving the Rally?
BRKR shares surge 66.3% in a year, fueled by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.
-
3 weeks ago benzinga.com
Barclays Maintains Overweight on Bruker, Raises Price Target to $70
Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the price target from $58 to $70.
3 weeks ago gurufocus.com
Bruker Corp (BRKR) Shares Fall 5.3% -- GF Value Says Still Overvalued
On October 06, 2026, Bruker Corp (BRKR) shares fell 5.3% to a current price of $60.50, moving within a 52-week range of $32.37 to $66.98. This drop comes amidst
3 weeks ago businesswire.com
Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution
BERLIN--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform,…
1 month ago zacks.com
Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
1 month ago defenseworld.net
Bruker (NASDAQ:BRKR) Sets New 1-Year High – Should You Buy?
Bruker Corporation (NASDAQ: BRKR - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $65.48 and last traded at $65.25, with a volume of…
1 month ago investorplace.com
Neuralink Stock: How to Invest Before the IPO
You can't buy Neuralink stock yet, but its supply chain is already public. Here are the brain-computer interface stocks to watch before the Neuralink IPO.
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Bruker, Raises Price Target to $72
Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and raises the price target from $70 to $72.
-
1 month ago benzinga.com
Leerink Partners Maintains Outperform on Bruker, Raises Price Target to $80
Leerink Partners analyst Puneet Souda maintains Bruker (NASDAQ:BRKR) with a Outperform and raises the price target from $60 to $80.
1 month ago gurufocus.com
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
At the Human Proteome Organization World Congress 2026, [url="]Bruker Corporation[/url] (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni wor
1 month ago businesswire.com
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
SINGAPORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows…
1 month ago marketbeat.com
Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound
Bruker NASDAQ: BRKR CFO Gerald Herman said the company's second-quarter results reflected stronger-than-expected organic order bookings and earnings per share, while revenue came in later than…
1 month ago seekingalpha.com
Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
-
1 month ago benzinga.com
Bruker Wins Major UC Berkeley Order For Advanced Research Systems
Bruker Corporation (NASDAQ:BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic…
1 month ago businesswire.com
Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley
BERKELEY, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic…
1 month ago seekingalpha.com
Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago benzinga.com
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.
-
1 month ago benzinga.com
UBS Maintains Neutral on Bruker, Raises Price Target to $65
UBS analyst Dan Leonard maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $45 to $65.
1 month ago seekingalpha.com
Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
1 month ago gurufocus.com
Bruker Corporation to Present at Upcoming Investor Conferences
[url="]Bruker Corporation[/url] (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences:Wells Fargo 21st Annual Heal
1 month ago businesswire.com
Bruker Corporation to Present at Upcoming Investor Conferences
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences: Wells Fargo 21st Annual…
-
1 month ago benzinga.com
Bruker, Luvata Team Up To Boost Superconductor Supply For Fusion Power Projects
Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (NASDAQ:BRKR), and Luvata Materials & Solutions, a Business Unit of Luvata Group (LUVATA) today announced a strategic…
1 month ago gurufocus.com
BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion
Bruker Energy and Supercon Technologies (BEST), a segment of [url="]Bruker Corporation[/url] (Nasdaq: BRKR), and Luvata Materials and Solutions, a Business Unit of
1 month ago businesswire.com
BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion
HANAU, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (Nasdaq: BRKR), and Luvata Materials & Solutions, a Business Unit of…
1 month ago zacks.com
Why Is Bruker (BRKR) Up 12.5% Since Last Earnings Report?
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?
2 months ago benzinga.com
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit
10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.
-
2 months ago benzinga.com
Citigroup Maintains Neutral on Bruker, Lowers Price Target to $53
Citigroup analyst Brendan Digan maintains Bruker (NASDAQ:BRKR) with a Neutral and lowers the price target from $60 to $53.
2 months ago benzinga.com
S&P 500 Hits Record Highs, Palantir Jumps 27%: Stock Market Today
The S&P 500 and Dow set records as Palantir and Caterpillar earnings powered chips higher, while crude slid 5%.
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular session. The company's market cap stands at $1.9 million. Adagio Medical Holdings (NASDAQ:ADGM) shares…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings…
-
2 months ago benzinga.com
Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Lowers FY2026 Sales Guidance from $3.570B-$3.600B to $3.540B-$3.570B vs $3.589B Est
Bruker (NASDAQ:BRKR) affirms FY2026 Adj EPS guidance from $2.10-$2.15 to $2.10-$2.15 vs $2.12 analyst estimate. Lowers FY2026 sales outlook from $3.570 billion-$3.600 billion to $3.540 billion-$3.570…
-
2 months ago benzinga.com
Bruker Q2 Adj. EPS $0.49 Beats $0.39 Estimate, Sales $838.500M Miss $853.543M Estimate
Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.39 by 25.64 percent. This is a 53.12 percent increase over earnings of $0.32 per…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-market session. The market value of their outstanding shares is at $5.1 million. Advanced Biomed…
-
3 months ago benzinga.com
Bruker Acquires The DISQVER Clinical Metagenomics Platform From Noscendo; Financial Terms Not Disclosed
The DISQVER® platform provides advanced bioinformatics and reporting to support rapid and comprehensive WGS analysis directly from cell-free human blood samplesDISQVER® enables metagenomic…
-
3 months ago benzinga.com
Citigroup Maintains Neutral on Bruker, Raises Price Target to $60
Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $44 to $60.
-
3 months ago benzinga.com
Leerink Partners Maintains Outperform on Bruker, Raises Price Target to $70
Leerink Partners analyst Puneet Souda maintains Bruker (NASDAQ:BRKR) with a Outperform and raises the price target from $60 to $70.
-
4 months ago benzinga.com
Guggenheim Maintains Buy on Bruker, Raises Price Target to $70
Guggenheim analyst Subbu Nambi maintains Bruker (NASDAQ:BRKR) with a Buy and raises the price target from $50 to $70.
-
4 months ago benzinga.com
Barclays Maintains Overweight on Bruker, Raises Price Target to $60
Barclays analyst Luke Sergott maintains Bruker (NASDAQ:BRKR) with a Overweight and raises the price target from $53 to $60.
-
4 months ago benzinga.com
Bruker Corp Files Prospectus For Mixed Shelf Offering, Size Not Disclosed
Bruker CorporationCommon StockPreferred StockDebt SecuritiesWarrantsUnitsDepositary SharesSubscription RightsPurchase ContractsFrom time to time, we may offer and sell any combination of the…
-
5 months ago benzinga.com
Bruker's Microbiology & Infection Diagnostic Division Showcases Expanding Portfolio, Innovations Throughout Microbial Identification, Sepsis Diagnostics, Molecular Testing, And NGS Workflows
At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification,…
-
5 months ago benzinga.com
At ASMS, Bruker Launches TimsMRMS System, Focused On Trapped Ion Mobility Separation To Ultra-high-resolution Magnetic Resonance Mass Spectrometry
Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor ManufacturingLaunch of eXtreme 10M resolution novel timsMRMS™ mass…
-
5 months ago benzinga.com
Bruker Announces Commissioning Of BioSpec 18 Tesla Preclinical MRI At Champalimaud Foundation In Lisbon, Portugal
World's highest-field MRI system provides leading disease biology research capabilitiesBruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's…
-
5 months ago benzinga.com
UBS Maintains Neutral on Bruker, Raises Price Target to $45
UBS analyst Dan Leonard maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $40 to $45.
-
5 months ago benzinga.com
Citigroup Maintains Neutral on Bruker, Raises Price Target to $44
Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Neutral and raises the price target from $40 to $44.